Orlance, Inc.


Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions.  Leveraging $13M in NIH SBIR funding, Orlance has developed the MACH-1 platform to epidermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is positioned to increase access and compliance. The company’s lead assets, including a universal influenza DNA vaccine, are at Pre-IND stage and are poised for Phase 1 clinical trial readiness by Q4 2024.